Avantor stock price target cut to $26 at Stifel

On Monday, Stifel analysts adjusted their outlook on Avantor Inc . (NYSE:AVTR), reducing the price target to $26 from the previous $28 while maintaining a Buy rating on the shares. The adjustment follows management’s recent commentary regarding their 2025 EBITDA goals, which suggested aiming for the higher end of the guidance range, a target that analysts found unexpectedly ambitious. The company currently generates EBITDA of $1.13 billion on revenues of $6.78 billion. According to InvestingPro analysis, Avantor appears to be trading near its Fair Value.

The company’s stock experienced a notable decline on Friday, dropping by 12%. InvestingPro data confirms this sharp decline, showing a one-week return of -12.39%, with the stock now trading near its 52-week low. Analysts at Stifel noted that this reaction might have been an overreaction to the EBITDA targets, although they acknowledged that a downward adjustment was inevitable. They pointed out that investor confidence in Avantor had been largely tied to its cost reduction strategies and potential for margin improvement, with the company maintaining a healthy gross profit margin of 33.6%.

Stifel’s analysis highlighted several key strengths in Avantor’s investment case. Despite the reduced price target, the firm emphasized the company’s attractive valuation, minimal exposure to the Chinese market, and a low mix of instrument sales as compelling reasons for maintaining a Buy rating on the stock. This aligns with the broader analyst consensus of 1.95 (Buy) on InvestingPro, which offers 8 additional valuable insights about Avantor’s financial health and market position through its comprehensive Pro Research Report.

The analysts also remarked on the broader market context, indicating that the overall performance of the Tools sector was poor, which likely contributed to Avantor’s stock movement on Friday. Despite these challenges, Stifel remains positive about Avantor’s long-term prospects based on its strategic position and market fundamentals.

Investors and market watchers will continue to monitor Avantor’s performance, particularly in light of the company’s ambitious EBITDA goals and the strategies it plans to implement to achieve them. The reduced price target reflects a cautious but still optimistic outlook, with the company’s core strengths expected to support its growth trajectory.

In other recent news, Avantor, Inc. reported its fourth-quarter 2024 results, with an earnings beat but a revenue shortfall. The company reported adjusted earnings per share of $0.27, surpassing the analyst estimate of $0.26. However, revenue for the quarter came in at $1.69 billion, missing the consensus estimate of $1.71 billion, marking a 2% decrease year over year.

Avantor’s bioprocessing platform experienced high-single-digit growth, with expectations of continued strength due to focused execution and improving end market conditions. For the full year 2024, Avantor reported net sales of $6.78 billion, a 3% decrease compared to 2023, with an organic decline of 2%.

Adjusted EBITDA for the year was $1,198.8 million, with an adjusted EBITDA margin of 17.7%. These recent developments underscore the company’s resilience amidst changing market conditions. CEO Michael Stubblefield expressed confidence in achieving both near-term and long-term financial goals, citing Avantor’s industry-leading portfolio and efficient operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.